CoChat
Sign Up
Cited by 217Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Opioid Use

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

Iskedjian, Michael, Bereza, Basil, Gordon, Allan, Piwko, Charles, Einarson, Thomas R.·2007·Current Medical Research and Opinion
DOI 10.1185/030079906x158066
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Debilitating pain, occurring in 50-70% of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain. DATA SOURCES: Studies were identified from Medline, Embase, and Cochrane databases; Bayer Healthcare provided additional trials. STUDY SELECTION: Accepted were randomized, double-blinded placebo-controlled trials of cannabinoid-based treatments for MS-related/neuropathic pain in adults > or = 18 years of age. DATA EXTRACTION: Two reviewers identified studies and extracted data; a third adjudicated disagreements. Data included baseline and endpoint pain scores on visual analog or 11-point ordinal scales. DATA SYNTHESIS: Of 18 articles and three randomized controlled trial (RCT) reports identified, 12 articles and two reports were rejected (9 = inappropriate disease or outcome, 1 = duplicate, 1 = review, and 1 = abstract); six accepted articles and one RCT-report involved 298 patients (222 treated, 76 placebo); four examined Sativex (a cannabidiol/delta-9-tetrahydrocannabinol (THC) buccal spray) (observations = 196), five cannabidiol (n = 41), and three dronabinol (n = 91). Homogeneity chi(2) values were non-significant, allowing data combination. Analyses focused on baseline-endpoint score differences. The cannabidiol/THC buccal spray decreased pain 1.7 +/- 0.7 points (p = 0.018), cannabidiol 1.5 +/- 0.7 (p = 0.044), dronabinol 1.5 +/- 0.6 (p = 0.013), and all cannabinoids pooled together 1.6 +/- 0.4 (p < 0.001). Placebo baseline-endpoint scores did not differ (0.8 +/- 0.4 points, p = 0.023). At endpoint, cannabinoids were superior to placebo by 0.8 +/- 0.3 points (p = 0.029). Dizziness was the most commonly observed adverse event in the cannabidiol/THC buccal spray arms (39 +/- 16%), across all cannabinoid treatments (32.5 +/- 16%) as well as in the placebo arms (10 +/- 4%). CONCLUSION: Cannabinoids including the cannabidiol/THC buccal spray are effective in treating neuropathic pain in MS. LIMITATIONS: This review was based on a small number of trials and patients. Pain related to MS was assumed to be similar to neuropathic pain.

Overview

Integrity signals

Registry

Crossref · 10.1185/030079906x158066

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 6

  1. Bruck G, 2003, Neurol Sci, 24, S265–S267
  2. Burks J, 1992, J Neurol Rehabil, 6, 131
  3. Solaro C, 2003, Pain and MS. Int MS J, 10, 14
  4. Indaco A, 1994, Acta Neurol Scand, 16, 97
  5. Jungmayr P, 2004, Deutsche Apoteker Zeitung, 144, 42
  6. Nurimikko TJ, 2005, Neurology, 64, A374

Cited by

Sorted by citations

Items 201–217 of 217

Related

See all

Metadata

Authors
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R.
Affiliations
  • PharmIdeas (Canada) (CA)
  • Mount Sinai Hospital (CA)
  • University of Toronto (CA)
Corresponding author
Einarson, Thomas R.
ORCID
Venue
Current Medical Research and Opinion
Publisher
Informa Healthcare
Published
2006-11-27
Volume
23
Issue
1
Pages
17-24
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
DOI
10.1185/030079906x158066
OpenAlex
W2146626244
Cited by
216
References
38
Citations by year
2026: 3 · 2025: 2 · 2024: 5 · 2023: 20 · 2022: 13 · 2021: 15 · 2020: 16 · 2019: 8 · 2018: 16 · 2017: 11 · 2016: 9 · 2015: 13 · 2014: 9 · 2013: 7 · 2012: 11
FWCI
1.52
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bayer HealthCare
  • Bayer Canada
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
neuropathic pain, multiple sclerosis, Sativex, cannabidiol, dronabinol, THC, analgesia, adverse events, dizziness, drug safety, VAS pain score, quality of life
MeSH terms
Cannabinoids, Humans, Multiple Sclerosis, Neuralgia, Pain, Pain Measurement, Chi-Square Distribution, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review